Column

Today we would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model (Murakami et al., Cells., 2022).

 
In this paper, the authors evaluated the effect of pemafibrate, a selective PPARa modulator, and tofogliflozin, an inhibitor of Na+/glucose-conjugated transport carrier 2, alone and in combination on the progression of NASH. The use of pemafibrate and tofogliflozin, compounds with different mechanisms, was shown to have a synergistic effect.

STAM^TM

NASH is now considered to be a fatty liver disease with a variety of metabolic abnormalities, rather than simply non-alcoholic steatohepatitis. This has lead many to the idea that treating the disease, not with a single drug, but with a combination of drugs that target multiple indications, to be the best approach for treating NASH. This paper also assesses their drugs potential to inhibit the progression of NASH-derived liver cancer, which has garnered a lot of attention in recent years.

Our STAM^TM model was used to conduct the analysis in this paper. The STAM^TM model is the world’s first mouse model to show the progression of NASH to liver cancer, and was developed here, at SMC Laboratories. This model shows a pathology similar to human NASH (fatty liver → NASH → liver fibrosis → HCC). Therefore, the STAM^TM model has been used in many efficacy studies, as well as in basic research, and has also been used to test the effects of combination therapy with various compounds.
 
Would you like to use the STAM^TM model to test the efficacy of your compound in monotherapy or combination therapy? We can use our years of experience to offer you a study design that is tailored to suit your needs.